TELA Bio (TELA) investor relations material

Company overview and business model

• Commercial-stage medical technology company focused on innovative soft-tissue reconstruction solutions that prioritize preservation and restoration of patient anatomy.

• Product portfolio includes OviTex for hernia repair and abdominal wall reconstruction, and OviTex PRS for plastic and reconstructive surgery, both leveraging biologic and polymer materials.

• Products are supported by clinical data, including the BRAVO and OPERA studies, and have received multiple FDA 510(k) clearances.

• Distribution includes a direct sales force in the U.S. and Europe, partnerships with group purchasing organizations, and select commercial partnerships for complementary products.

• Intellectual property portfolio and exclusive manufacturing agreement with Aroa Biosurgery Ltd. provide competitive advantages and cost efficiencies.

Financial performance and metrics

• Estimated annual U.S. total addressable market for OviTex products is approximately $1.8 billion; for OviTex PRS, approximately $800 million.

• Recent commercial launches and product expansions, including new configurations and larger sizes, aim to capture additional market share.

Use of proceeds and capital allocation

• No proceeds from the resale of shares by the selling stockholder; proceeds from any cash exercise of the warrant will be used for general corporate purposes, including sales and marketing, R&D, general and administrative matters, working capital, and capital expenditures.